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A B S T R A C T
Objective: To characterize the profile of non-AIDS-related comorbidities (NARC) in the older HIV-1-
infected population and to explore the factors associated with multiple NARC.
Methods: This was a multicentre, cross-sectional study including HIV-1-infected patients aged 50 years,
who were virologically suppressed and had been on a stable antiretroviral therapy (ART) regimen for at
least 6 months. A multiple regression model explored the association between demographic and clinical
variables and the number of NARC.
Results: Overall, 401 patients were enrolled. The mean age of the patients was 59.3 years and 72.6% were
male. The mean duration of HIV-1 infection was 12.0 years and the median exposure to ART was 10.0
years. The mean number of NARC was 2.1, and 34.7% of patients had three or more NARC.
Hypercholesterolemia was the most frequent NARC (60.8%), followed by arterial hypertension (39.7%)
and chronic depression/anxiety (23.9%). Arterial hypertension and diabetes mellitus were the most
frequently treated NARC (95.6% and 92.6% of cases, respectively). The linear regression analysis showed a
positive relationship between age and NARC (B = 0.032, 95% confidence interval 0.015–0.049; p = 0.0003)
and between the duration of HIV-1 infection and NARC (B = 0.039, 95% confidence interval 0.017–0.059;
p = 0.0005).
Conclusions: A high prevalence of NARC was found, the most common being metabolic, cardiovascular,
and psychological conditions. NARC rates were similar to those reported for the general population,
suggesting a larger societal problem beyond HIV infection. A multidisciplinary approach is essential to
reduce the burden of complex multi-morbid conditions in the HIV-1-infected population.
© 2018 Merck Sharp & Dohme Corp and The Authors. Published by Elsevier Ltd on behalf of International
Society for Infectious Diseases This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The success and wide availability of combination antiretro-
viral therapy (ART) has led to a paradigm shift in developed
countries from HIV being a fatal disease to a manageable
chronic illness (Deeks et al., 2013). As a result, morbidity and
mortality have decreased dramatically (Palella et al., 1998;
Weber et al., 2013). Infected individuals are living longer and
the HIV population is aging, with a life-expectancy approach-
ing that of the general population (Samji et al., 2013; May et al.,
2014).
An estimated 10% of people living with HIV worldwide are over
the age of 50 years. This estimate can be as high as 50% in
developed regions and will continue to rise as ART becomes more
readily available and/or is introduced sooner (High et al., 2012;
Joint United Nations Programme on HIV/AIDS (UNAIDS), 2013).
This phenomenon has been accompanied by an increasing
number of patients diagnosed at older ages who are also
diagnosed later during the course of the disease (US Centers
for Disease Control and Prevention (CDC), 2016; Tavoschi et al.,
2017). Aging of the HIV population has led to a shift in the causes
of death of infected individuals and to a growing impact of non-
AIDS-related comorbidities (NARC) (Costagliola, 2014; Schouten
et al., 2014). People infected with HIV may suffer from accelerated
aging (Effros et al., 2008; Deeks 2009; Pathai et al., 2014), i.e.,
being considered elderly at the age of 50 years (Blanco et al.,
2012), although this is the subject of debate (Rasmussen et al.,
2015). They also present an earlier onset (Guaraldi et al., 2011)
and higher prevalence (Costagliola, 2014; Smit et al., 2015) of
comorbidities that are typically associated with aging. These
include non-AIDS-related malignancies (Kirk et al., 2007; Silver-
berg et al., 2015), diabetes mellitus (Guaraldi et al., 2011; Hasse
et al., 2011; Vance et al., 2011; Torres et al., 2013), hyperlipidemia
(Manrique et al., 2010; Wu et al., 2012), cardiovascular disease
(Triant et al., 2007; Freiberg et al., 2013; Althoff et al., 2015),
arterial hypertension (Hasse et al., 2011; Oursler et al., 2011;
Torres et al., 2013), kidney disease (Guaraldi et al., 2011; Vance
et al., 2011), and reduced bone mineral density (Triant et al., 2007;
Onen et al., 2010).
Comorbidities are associated with the natural aging process,
but an increased risk of comorbidities in older HIV patients has
been linked to the long-term use of ART, chronic inflammation,
and persistent immune activation due to HIV infection (Strategies
for Management of Antiretroviral Therapy Study Group et al.,
2008; Guaraldi et al., 2011; Schouten et al., 2014). In addition,
management of the disease in this aging population is compli-
cated by polypharmacy/drug–drug interactions and toxicity
(Simone and Appelbaum, 2008). For instance, interactions of
some lipid-lowering agents or anticonvulsants with ART regi-
mens have been reported (Lennox et al., 2014; Rockstroh et al.,
2013; University of Liverpool, 2018). This raises new treatment
challenges that require improved clinical management and
optimization of health resources to better address the needs of
this population.
In 2015, there were 53 072 people diagnosed with HIV infection
in Portugal, and since the beginning of the HIV epidemic, 14.6% of
the reported cases have been among people aged 49 years. This
number increased to over 25% of the 1220 newly diagnosed cases
in 2014 (Direcção Geral Saúde, 2015). Despite these escalating
numbers, NARC in aging HIV patients has not been characterized in
Portugal.
The main purpose of this study was to characterize the profile of
NARC, concurrent medications, and use of health resources among
HIV-1 patients aged 50 years followed at HIV care centres. In
addition, factors associated with the presence of multiple NARC
were analyzed.Methods
Study design and participants
This was a cross-sectional, observational study conducted
between November 2015 and June 2016 in seven Portuguese
centres specializing in the management of HIV/AIDS. These centres
are mainly located in the Lisbon and Oporto regions and covered
approximately 60% of HIV cases followed in the outpatient setting
in the country in 2014 (Direcção Geral Saúde, 2015).
HIV-1-positive patients aged 50 years were included consec-
utively in the study according to their scheduled appointment.
Patients had to have been on a stable ART regimen for at least 6
months prior to enrolment, with undetectable plasma HIV RNA
(<50 copies/ml) during the same period. Patients who were unable
or unwilling to comply with study procedures according to the
investigator’s judgement were excluded (e.g., not being mentally
capable of providing reliable information regarding concomitant
medications).
Variables and sources of information
Socio-demographic data (age, sex, race, and country of origin),
addictive behaviours (smoking, i.e., currently smoking or past/
never smoked, alcoholism, and illicit drug use), HIV-1 infection
characteristics (mode of transmission, duration of infection,
plasma HIV RNA and CD4 count at presentation, last CD4/CD8
ratio, and CDC HIV stage), and ART data (regimen, duration, and
number of previous regimens) were obtained from the medical
records and through patient interview. The duration of infection
was defined as the time elapsed from the year of diagnosis to the
year of the study appointment.
The diagnosis of NARC of interest was obtained from the
medical records and included diabetes mellitus, hypercholesterol-
emia, arterial hypertension, acute myocardial infarction, stroke,
renal failure, renal lithiasis, chronic hepatitis C, chronic hepatitis B,
emphysema/bronchitis, non-AIDS-related malignancies, osteopo-
rosis, and depression/chronic anxiety. These variables were
considered of interest to the authors, based on two criteria: the
reported high prevalence in the aging population, or the clinical
relevance in the HIV-1-infected population.
Co-medications of interest included lipid-lowering agents,
antihypertensives, antidepressants or anxiolytics, insulin or oral
antidiabetics, antiplatelet or anticoagulants, bronchodilators,
inhaled or other types of steroid, and treatments for osteoporosis.
The number and duration of hospitalizations and the number of
medical appointments at the HIV specialist (and other specialties)
and the general practitioner over the previous 12 months were also
collected.
The study was approved by the ethics committee of each centre
and all participants provided written informed consent prior to
enrolment.
Statistical analysis
Continuous variables were summarized as the mean, median,
standard deviation (SD), and/or range and categorical variables
were summarized as the absolute and relative frequencies.
The association between the presence and number of NARC
and the following independent variables of interest were
explored: sex, age, duration of infection and ART (cut-offs for
the last two variables were 6 months–1 year, 1–5 years, 5–10
years, 10–15 years, 15–20 years, and 20 years), time to
presentation (late presentation: CD4 count <350 cells/mm3;
non-late presentation: CD4 count 350 cells/mm3), CD4 count
<200 cells/mm3, and last CD4/CD8 ratio.
Table 1
Socio-demographic and HIV-1 infection characteristics of the study participants.
Total number of participants 401
Age (years), mean  SD (range) 59.4  7.5 (50–87)
Sex
Male 291 (72.6)
Female 110 (27.4)
Race
Caucasian 365 (91.2)
Other 35 (8.8)
Missing 1
Country of origin
Portugal 372 (92.8)
Other 29 (7.2)
Smoking habits
Smoker (past or current) 191 (47.6)
Non-smoker 210 (52.4)
Chronic alcoholism
Yes 31 (7.7)
No 370 (92.3)
Illicit drug use
Never 332 (82.8)
Past 59 (14.7)
Current 10 (2.5)
Duration of infectiona (years), mean  SD (range) 12.0  6.2 (1–29)
Mode of transmission
Heterosexual contact 266 (66.3)
Men who have sex with other men 65 (16.2)
Intravenous drug use 59 (14.7)
Parenteral 1 (0.2)
Other 10 (2.5)
Plasma HIV-1 RNA at presentation (copies/ml),
median (range)
102 000 (20–1 107)
Missing 68
CD4 count at presentation (cells/mm3), median (range) 272 (1–1255)
Missing 40
Late presentation (CD4 < 350 cells/mm3)
Yes 214 (59.3)
No 147 (40.7)
CD4 < 200 cells/mm3
Yes 148 (41.0)
No 213 (59.0)
Last CD4 count (cells/mm3), median (range) 589 (10–2195)
Change in CD4 countb (cells/mm3), mean  SD 327  319
Missing 40
CD4/CD8 ratio – last measurement, median (range) 0.80 (0.10–3.40)
CDC HIV-1 stagec
A1 78 (20.1)
A2 106 (27.3)
A3 50 (12.9)
B1 10 (2.6)
B2 21 (5.4)
B3 19 (4.9)
C1 7 (1.8)
C2 11 (2.8)
C3 86 (22.2)
SD, standard deviation. Data are presented as the number and percentage, unless
otherwise specified. Reasons for non-eligibility included change of ART regimen in
the past 6 months (n = 1) and patient inability to provide reliable information during
the study appointment (n = 1).
a Time elapsed from the year of presentation to the year of study appointment.
b From presentation to last CD4 cell count.
c AIDS diagnosis corresponding to one of the following stages: C1, C2, C3, A3, or B3.
96 R. Serrão et al. / International Journal of Infectious Diseases 79 (2019) 94–100The Chi-square test and Kruskal–Wallis non-parametric test
were used to explore the association of categorical and continuous
independent variables of interest with the grouped number of
NARC (0, 1, 2, 3). The Kruskal–Wallis test was used to compare
ART regimens regarding NARC and co-medications. Spearman’s
correlation coefficient was used to correlate the number of NARC
with the duration of infection, duration of ART, last CD4/CD8 ratio,
and use of health resources.
The association between categorical and continuous indepen-
dent variables of interest and the presence of at least one NARC was
measured with the Chi-square test (or Fisher’s exact test) and
Mann–Whitney non-parametric test for continuous variables,
respectively.
A multivariable linear regression model (beta regression
coefficient, B) and 95% confidence intervals (95% CI) and p-values
were used to determine the association of independent variables
with the number of NARC.
All variables of interest with p < 0.20 in the bivariate analysis
were included in the multivariable regression model. Only the
variables with statistically significant B were included in the
optimized linear model. Goodness-of-fit was assessed using the
R-squared test (R2) for the number of NARC.
All comparisons were two-tailed and statistical significance
was set at 5%. SAS software version 9.4 (SAS Institute Inc, Cary, NC,
USA) was used for all analyses.
Results
Socio-demographic and clinical characteristics
Overall, 401 patients were included, of whom 72.6% were male.
The mean age of the study patients was 59.3  7.5 years (Table 1).
Nearly half of the patients (47.6%) were past or current smokers,
7.7% were chronic alcoholics, and 17.2% were past or current users
of illicit drugs.
The mean duration of HIV-1 infection was 12.0  6.2 years
and the most frequent mode of transmission was heterosexual
contact (66.3%). The median CD4 count at presentation was
272 cells/mm3, with 59.3% of patients being late presenters (CD4
count <350 cells/mm3) and 41% of patients presenting a CD4
count <200 cells/mm3. The median value of the most recent CD4
count was 589 cells/mm3. A mean increase of 327 CD4 cells/mm3
was observed between the latest CD4 count and the measure-
ment obtained at presentation. An AIDS diagnosis was made in
44.6% of patients (Table 1).
HIV-1 treatment and use of health resources
The mean duration of exposure to ART was 10.4 years, with 8.0%
of patients having received the treatment for 20 years or more
(Table 2). The median time from diagnosis to initiation of ART was
1.6  2.7 years. The mean cumulative number of ART regimens was
3.0  1.93, and 19.5% of patients had received five or more
regimens. The median duration of the current ART regimen was
2.0 years (range 0.0–15.0 years) and the most frequent class of ART
used was non-nucleoside reverse transcriptase inhibitors (NNRTI)
(52.9% of patients), followed by protease inhibitors (24.4%) and
integrase inhibitors (17.0%).
All patients had attended at least one appointment with an
HIV specialist in the previous 12 months (median of three
appointments, range 1–43 appointments), 49.0% had attended
other specialist appointments, and 56.4% had attended
appointments at the general practitioner. Twenty-eight
patients (7.2%) had been hospitalized in the previous year
(mean of 1 hospitalization), with a median duration of 7 days
(range 1–37 days).NARC and co-medications
The large majority of patients (90%) had at least one NARC (the
mean number was 2.1 and median was 2.0 (range 0–6)) and nearly
35% had three or more NARC (Table 3). The most frequent NARC
was hypercholesterolemia (60.8% of patients), followed by arterial
hypertension (39.7%). Other NARC included chronic anxiety/
depression (23.9% of patients), chronic hepatitis C (14.2%), diabetes
mellitus (13.5%), and renal lithiasis (11.2%).
Nearly half of the patients (49.6%) were being treated with
lipid-lowering agents, followed by antihypertensives (39.4%) and
antidepressant/anxiolytic drugs (17.7%) (Table 3).
Table 2
Antiretroviral therapies and use of health resources.
Number of participantsa 400
ART durationb (years), median (range) 10.0 (1–27)
6 months–1 year 0 (0.0)
1–5 years 87 (21.8)
5–10 years 111 (27.8)
10–15 years 93 (23.3)
15–20 years 77 (19.3)
20 years 32 (8.0)
Number of ART regimens, mean  SD 3.0  1.9
Patient had 5 ART regimens
No 322 (80.5)
Yes 78 (19.5)
Time from diagnosis to ART initiation (years),
median (range)
1.6  2.7
Current ART durationc (years), median (range) 2.0 (0.0–15.0)
ART at study appointment
Protease inhibitors (PI) 98 (24.4)
NNRTI 212 (52.9)
Integrase inhibitors 68 (17.0)
PI + NNRTI 1 (0.2)
Other ART 22 (5.5)
Use of health resources over the past 12 months
Medical appointments at HIV specialist (n = 394) 394 (100.0)
Number of appointments at HIV specialist,
mean  SD (range)
3.43  2.72 (1.0–43.0)
Appointments at other specialty (n = 384) 188 (49.0)
Number of appointments at other specialty,
mean  SD (range)
3.50  3.48 (1.0–25.0)
Appointments at general practitioner (n = 275) 155 (56.4)
Number of appointments at general practitioner,
mean  SD (range)
3.58  3.48 (1.0–17.0)
Hospitalizations during the previous year (n = 391) 28 (7.2)
Number of hospitalizations, mean  SD (range) 1.11  0.31 (1–2)
Duration of hospitalization (days), median (range)
(n = 31)
7.0 (1–37)
ART, antiretroviral therapy; SD, standard deviation; NNRTI, non-nucleoside reverse
transcriptase inhibitor. Data are presented as number and percentage, unless
otherwise specified.
a Sample from which proportions were calculated.
b Years elapsed from first ART to study appointment.
c For incomplete dates, the following assumptions were considered: if only the
year was known, the date considered was July 1; if only the day was unknown, the
15th day of the given month was considered.
Table 3
Non-AIDS-related comorbidities and co-medications.
Total number of participants 401
At least one non-AIDS-related comorbidity, n (%) 361 (90.0)
1 116 (28.9)
2 106 (26.4)
3 139 (34.7)
Non-AIDS-related comorbidities
Mean  SD 2.1  1.34
Median (range) 2.0 (0–6)
Distribution of non-AIDS-related comorbidities, n (%)
Hypercholesterolemia 244 (60.8)
Arterial hypertension 159 (39.7)
Depression/chronic anxiety 96 (23.9)
Chronic hepatitis C 57 (14.2)
Diabetes mellitus 54 (13.5)
Renal lithiasis 45 (11.2)
Emphysema/bronchitis 36 (9.0)
Non-AIDS-related malignancy 32 (8.0)
Renal failure 32 (8.0)
Osteoporosis 23 (5.7)
Chronic hepatitis B 17 (4.2)
Acute myocardial infarction 14 (3.5)
Stroke 15 (3.7)
Co-medications of interest at study appointment, n (%)
Lipid-lowering agents 199 (49.6)
Antihypertensives 158 (39.4)
Antidepressants/anxiolytics 71 (17.7)
Insulin/oral antidiabetics 52 (13.0)
Antiplatelet/anticoagulants 46 (11.5)
Bronchodilators, inhaled steroids or others 27 (6.7)
Osteoporosis treatment 24 (6.0)
Hepatitis C treatment 7 (1.7)
NARC being treated at study appointment, n (%)
Arterial hypertension 152 (95.6)
Diabetes mellitus 50 (92.6)
Acute myocardial infarction 12 (85.7)
Hypercholesterolemia 194 (79.5)
Osteoporosis 18 (78.3)
Stroke 11 (73.3)
Depression/chronic anxiety 68 (70.8)
Emphysema/bronchitis 24 (66.7)
Chronic hepatitis Ca 7 (12.3)
SD, standard deviation; NARC, non-AIDS-related comorbidities.
a Of the patients not being treated for chronic hepatitis C at the study
appointment, 72.0% (41/50) were cured from this infection and 11.0% (9/50) were
awaiting treatment.
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treated with antihypertensives at the time of the study appoint-
ment and 92.6% of the patients with diabetes mellitus were being
treated with insulin or oral antidiabetics. Chronic hepatitis B,
hypercholesterolemia, osteoporosis, acute myocardial infarction,
and depression/chronic anxiety were the other conditions where
the proportion of patients on treatment was above 70%.
Association of independent variables of interest with the number of
NARC
The bivariate analysis showed that age and duration of HIV-1
infection were significantly associated with the number of NARC
(Supplementary material Table S1).
The optimized multiple linear regression model showed
modest statistically significant effects regarding age (B = 0.032,
95% CI 0.015–0.049; p = 0.0003) and duration of HIV-1 infection
(B = 0.039, 95% CI 0.017–0.059; p = 0.0005) with the number of
NARC (Table 4).
Table 5 shows the associations between the use of health
resources and the number of NARC. The number of medical
appointments at non-HIV hospital specialists (r = 0.2112;
p = 0.0032) and the number of co-medications (r = 0.7511;
p < 0.0001) were correlated with the number of NARC.
For the three most prevalent ART regimens (NNRTI, protease
inhibitors, and integrase inhibitors), the median number of NARCwas 2.0 (p = 0.003). No statistically significant difference was found
between these ART regimens regarding the median number of
co-medications (p = 0.077; data not shown).
Discussion
In this study, it was found that the vast majority (90%) of HIV-1-
infected patients aged 50 years and older had at least one NARC.
This prevalence is particularly high when compared to cohort and
cross-sectional studies from other regions, which have reported
one or more NARC in 50–70% of older HIV patients (Hasse et al.,
2011; Rodriguez-Penney et al., 2013; Torres et al., 2013; Wu et al.,
2014). However, two surveys conducted in the USA showed a
prevalence of NARC over 90% (Brennan, 2009; Balderson et al.,
2013). In addition, patients in the present study had an average
number of two NARC, which is lower than other studies that have
reported an average of four or more (Vance et al., 2011; Balderson
et al., 2013). One third of our sample had three or more NARC.
The most common NARC was hypercholesterolemia. Interest-
ingly, the prevalence found is disproportionately higher when
compared to reports from other countries (60% vs. 30%) (Torres
et al., 2013; Wu et al., 2014). It is known that hypercholesterolemia
is commonly associated with long-term use of ART (Riddler et al.,
2007) and that both protease inhibitors and Nucleoside Reverse
Transcriptase Inhibitor (NRTI) are associated with HIV metabolic
Table 4
Multivariable linear regression model regarding the number of non-AIDS-related comorbidities.a
Initial model Optimized model
B 95% CI for B p-Value B 95% CI for B p-Value
Sex, n (%)
Male Reference
Female 0.233 0.055 to 0.52 0.112
Age (years) 0.032 0.015 to 0.049 0.0002 0.032 0.015 to 0.049 0.0003
Duration of infection (years)b 0.038 0.017 to 0.059 0.0004 0.039 0.017 to 0.059 0.0005
p-Value <0.0001 <0.0001
R2 0.052 0.049
B, beta regression coefficient; CI, confidence interval; R2, R-squared was used to test the goodness-of-fit of the model.
a The ‘duration of infection’ and the ‘duration of ART’ were eligible for inclusion in the multivariable model. However, due to the high correlation between the two variables,
only the former was included as it showed a higher association with the total number of non-AIDS-related comorbidities.
b Duration of infection was included as a continuous variable.
Table 5
Association between the use of health resources and the number of non-AIDS-related comorbidities.
Spearman’s correlation coefficient p-Value
Number of NARC vs. number of medical appointments at the HIV specialist 0.0804 0.1113
Number of NARC vs. number of medical appointments at other hospital specialist 0.2136 0.0032
Number of NARC vs. number of medical appointments at general practitioner 0.0867 0.2934
Number of NARC vs. number of hospitalizations during the previous year 0.0147 0.9408
Number of NARC vs. number of co-medications 0.7511 <0.0001
NARC, non-AIDS related comorbidities.
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infected patients (Gazzaruso et al., 2002). However, protease
inhibitors were used only by one quarter of participants. Moreover,
the duration of ART was not significantly associated with
hyperlipidemia in the regression analysis. Therefore, it is plausible
to assume that factors such as diet and lifestyle could largely have
contributed to the high prevalence of dyslipidemia among
participants. Epidemiological studies conducted in Portugal
showed a prevalence of hypercholesterolemia varying from 56%
to 69% (Instituto de Alimentação BECEL, 2000; Costa et al., 2003).
The Socrates study revealed that hypercholesterolemia was
frequently associated with higher body mass index, arterial
hypertension, and familial history of high cholesterol (Perdigão
et al., 2010).
Arterial hypertension and depression/anxiety were other
common NARC in this study (approximately 40% and 24%,
respectively), with proportions that corroborate other reports
(Manrique et al., 2010; Guaraldi et al., 2011; Hasse et al., 2011;
Vance et al., 2011; Wu et al., 2012, 2014; Torres et al., 2013). When
comparing the prevalence of NARC obtained in this study with the
NARC distribution available from the Portuguese Health National
Inquiry of 2014 for the general population 45 years of age, we
found a similar prevalence of arterial hypertension (39% vs. 41%,
respectively) and slightly higher prevalence of depression/anxiety
(23.9% vs. 16.7%) (Serviço Nacional de Saúde, 2014). In addition, a
comparable prevalence was found for diabetes (13.5% vs. 15.8%,
respectively), emphysema/bronchitis (9.0% vs. 8.2%), stroke (3.7%
vs. 2.6%), and acute myocardial infarction (3.5% vs. 2.4%). The
similar distribution of NARC rates found between HIV-infected
individuals and the general population suggests a larger societal
problem that is not restricted to the HIV infection setting. Factors
related to the aging process and to chronic diseases may be strong
contributors to the NARC distribution observed.
It was found that the duration of HIV-1 infection had a modest
statistically significant effect concerning the number of NARC, even
when adjusted for age.
Some studies have shown that longer ART exposure is an
independent predictor of polypathology (Phillips et al., 2008;
Guaraldi et al., 2011). However, in the linear regression model, astatistical association between this independent variable and the
number of NARC was found.
Not surprisingly, the distribution of co-medications being used
at the time of the study appointment was in line with the
distribution of NARC, with lipid-lowering agents, antihyperten-
sives, and antidepressants/anxiolytics being the most frequent.
Arterial hypertension and diabetes mellitus were the most
medicated conditions, with over 90% of patients receiving
treatment.
Of note, the high proportion of chronic hepatitis C patients
without treatment at the study appointment was due to the fact that
they were already cured of the infection or were still awaiting
treatment. Despite the small numbers analyzed, this finding should
be placed in the context of the emerging cure rates resulting from the
use of direct-acting antivirals in Portugal since 2015. It is expected
that the epidemiology pattern and management of HIV/hepatitis C
virus co-infection will change substantially in the near future.
Surprisingly, no correlation was found between the number of
co-medications and the number of NARC. One possible explanation
for this finding is that despite the diagnosis of a comorbid
condition, patients do not necessarily take the prescribed
medication (e.g., low financial resources or trying prophylactic
approaches first, such as diet or exercise among the patients with
lipid disorders). The reverse is also true, with patients often self-
prescribing medications without having the condition concerned
(e.g., antidepressants).
Patients with a higher number of NARC were more likely to visit
the non-HIV specialist.
The MSM mode of transmission was 16%, which is lower than
that described in other European reports. In 2012, MSM accounted
for 41.7% of newly reported HIV diagnoses in Western Europe
(European Centre for Disease Prevention and Control/WHO
Regional Office for Europe, 2013; Nakagawa et al., 2014). An
epidemiological study conducted in the northern region of
Portugal showed that only 26 out of the 289 individuals (9%)
reported MSM transmission (Carvalho et al., 2015). The highly
conservative culture of the Portuguese population may explain the
lower risk of MSM transmission in the older individuals compared
to other European populations of the same age group.
R. Serrão et al. / International Journal of Infectious Diseases 79 (2019) 94–100 99Despite Portugal having a large population of migrants, the vast
majority of individuals in the sample were Caucasian (>90%). This
could be explained by the fact that migrants in Portugal are usually
less compliant with HIV clinical appointments.
This study is subject to some limitations. First, specific
diagnosis criteria for NARC were not previewed in the protocol
and these data were drawn from the medical records. A potential
heterogeneity of diagnosis practices across institutions cannot be
excluded. Regarding hypercholesterolemia, the criteria defined in
the European Society of Cardiology (ESC) guidelines are widely
adopted by physicians in Portugal (Brignole et al., 2018). Second, an
age-matched HIV-1-uninfected population was not included to
compare the frequency of NARC, co-treatments, or use of health
resources. Nevertheless, it was found that the distribution of the
most prevalent NARC in this study was comparable to the NARC
distribution for the general population in 2014 for a similar age
stratum. Furthermore, this study focused only on comorbidities of
interest, those that are more frequently associated with the aging
process or found in the HIV-infected population. Capturing other
comorbid conditions would certainly enrich the findings. Past ART
regimens were not captured, so it was not possible to explore their
association with current conditions such as metabolic syndrome.
In addition, due to the cross-sectional design of the study, those
patients with a better prognosis and more engaged in dealing with
their HIV infection may have been included. This survival bias may
have more of an impact in the older age stratum.
The majority of participating sites did not systematically collect
the reason for non-eligibility. Although a consecutive sampling
method was implemented, which potentially minimizes selection
bias, the true magnitude of bias in this study cannot be ascertained.
In conclusion, this study provides a picture of the older HIV-1-
infected patient in Portugal, revealing a very high prevalence of
NARC. This poses several challenges regarding the management of
this condition and the need to adopt adequate treatment strategies
to deal with this potentially polymedicated population, particu-
larly in regard to the interactions of NNRTIs and protease inhibitors
with co-medications.
A multidisciplinary approach involving the expertise of
different fields of health care is essential to reduce the burden
of complex multi-morbid HIV infection in older people.
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